Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Events

Thumbnail
March 03, 2021

A busy year ahead for Parkinson’s disease

As several big pharma companies drop Parkinson’s projects, attention turns to gene therapies and repurposing diabetes drugs.

Thumbnail
March 01, 2021

Go or no go? A delayed decision on Evrenzo

March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.

Article image
Vantage logo
February 22, 2021

Biocryst looks to raise the profile of its factor D inhibitor

The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.

Article image
Vantage logo
February 13, 2021

Asco-GU – Clear blue water between Keytruda and kidney cancer rivals

Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.

Article image
Vantage logo
February 12, 2021

Asco-GU – confirmatory Padcev trial throws a curveball

Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.

Article image
Vantage logo
February 12, 2021

Novartis’s canakinumab cancer test approaches

Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?

Article image
Vantage logo
February 10, 2021

World Symposium – Orchard leads the crop of Hurler syndrome hopefuls

Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.

Article image
Vantage logo
February 09, 2021

Asco-GU – Bristol in pole position with Opdivo’s adjuvant use

Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.

Article image
Vantage logo
February 01, 2021

World Lung 2020 – amivantamab puts more data behind the hype

But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?

Article image
Vantage logo
January 30, 2021

World Lung 2020 – Yervoy’s front-line impotence laid bare

Full data show just how big a bust Keynote-598 is, though Bristol is unlikely to abandon hope.

Article image
Vantage logo
January 29, 2021

World Lung 2020 – no advance on Amgen’s “consistent” Kras promise

But the unveiling of sotorasib’s registrational dataset shows that bulls should be cautious of Mirati's numerical advantage.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.